argenx SE (NASDAQ:ARGX) Stock Position Boosted by Jennison Associates LLC

Jennison Associates LLC grew its stake in shares of argenx SE (NASDAQ:ARGX) by 27.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 302,149 shares of the company’s stock after buying an additional 64,183 shares during the quarter. Jennison Associates LLC’s holdings in argenx were worth $185,821,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ARGX. SG Americas Securities LLC grew its holdings in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after buying an additional 21 shares in the last quarter. Raymond James Trust N.A. grew its stake in argenx by 6.0% during the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock valued at $268,000 after acquiring an additional 28 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in shares of argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock valued at $286,000 after purchasing an additional 43 shares during the period. Aaron Wealth Advisors LLC lifted its position in shares of argenx by 10.1% in the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock worth $301,000 after purchasing an additional 45 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after purchasing an additional 56 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Citigroup upped their price objective on shares of argenx from $512.00 to $635.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Robert W. Baird downgraded shares of argenx from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Evercore ISI upped their target price on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, Wells Fargo & Company raised their price target on argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Price Performance

argenx stock opened at $655.13 on Monday. The firm has a fifty day moving average price of $632.58 and a two-hundred day moving average price of $571.05. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period last year, the business posted ($1.25) EPS. Analysts forecast that argenx SE will post 2.78 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.